Virtus ETF Advisers LLC Puma Biotechnology, Inc. Transaction History

Virtus ETF Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$6.5 - $10.73 $351,344 - $579,988	-54,053 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$8.75 - $12.85 $79,528 - $116,793	-9,089 Reduced 14.39%	54,053 $582,000
Q2 2019 Aug 13, 2019	BUY	$12.3 - $35.76 $366,097 - $1.06 Million	29,764 Added 89.17%	63,142 $803,000
Q1 2019 May 14, 2019	BUY	$20.77 - $42.37 $147,861 - $301,632	7,119 Added 27.11%	33,378 $1.3 Million
Q4 2018 Feb 05, 2019	BUY	$20.07 - $46.7 $241,482 - $561,894	12,032 Added 84.57%	26,259 $534,000
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $40,170 - $58,353	975 Added 7.36%	14,227 $652,000
Q2 2018 Aug 10, 2018	BUY	$48.3 - $68.25 $199,140 - $281,394	4,123 Added 45.16%	13,252 $784,000
Q1 2018 May 14, 2018	SELL	$59.7 - $99.25 $31,760 - $52,801	-532 Reduced 5.51%	9,129 $621,000
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $517,488 - $730,329	5,514 Added 132.96%	9,661 $955,000
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $27,360 - $45,505	380 Added 10.09%	4,147 $497,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,767	3,767 $329,000

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.